27 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release http://www.zacks.com/stock/news/590606/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-590606 Oct 29, 2019 - Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Festival honors former Quiksilver CEO Pierre Agnes, lost at sea in 2018 https://www.ocregister.com/2019/10/29/festival-honors-former-quiksilver-ceo-pierre-agnes-lost-at-sea-in-2018/ Oct 29, 2019 - Agnes disappeared during a storm while sailing off the coast of his native France.
Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings? http://www.zacks.com/stock/news/598310/is-a-beat-in-the-cards-for-regeneron-regn-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-598310 Nov 01, 2019 - Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View http://www.zacks.com/stock/news/598331/ironwood-irwd-beats-on-q3-earnings-revenues-ups-19-view?cid=CS-ZC-FT-analyst_blog|earnings_article-598331 Nov 01, 2019 - Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings? http://www.zacks.com/stock/news/598368/is-a-beat-in-the-cards-for-mallinckrodt-mnk-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-598368 Nov 01, 2019 - Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
WIll Allergan (AGN) Beat Estimates This Earnings Season? http://www.zacks.com/stock/news/598369/will-allergan-agn-beat-estimates-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-598369 Nov 01, 2019 - Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Allergan (AGN) Q3 Earnings Meet Estimates http://www.zacks.com/stock/news/604109/allergan-agn-q3-earnings-meet-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-604109 Nov 05, 2019 - Allergan (AGN) delivered earnings and revenue surprises of 0.00% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-604652 Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
3 Stocks for Value Investors to Buy as Market Reaches New High http://www.zacks.com/stock/news/644023/3-stocks-for-value-investors-to-buy-as-market-reaches-new-high?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-644023 Nov 27, 2019 - The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685884 Dec 24, 2019 - Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Pages: 123

Page 1>